World News: 17:23 GMT Tuesday 3rd December 2019. [GUERBET via Globe Newswire via SPi World News]
HCC is the most common primary liver cancer and is the fourth biggest cause of death due to cancer worldwide .
This medical device offers multiple advantages for healthcare professionals:
“” said Philippe Havard, Global Head of Marketing for Interventional Imaging - HCC and VAE
Vectorio is a sterile medical device set of class Is (CE 0459) intended to be used by healthcare professionals only. It is a Lipiodol resistant mixing and injection system for Trans-Arterial Chemo-Embolization (cTACE) procedures.For complete information please refer to country’s local Package Information Leaflet & Vectorio Instruction For Use (IFU). Vectorio is manufactured by Medex, a Guerbet group company.
Lipiodol Ultra-Fluid (ethyl esters of iodized fatty acids of poppyseed oil) was initially developed for diagnostic radiology in indications including liver lesion diagnosis, lymphography and hysterosalpingography, and then used in interventional radiology for conventional transarterial chemo-embolization (cTACE) procedures of multinodular hepatocellular carcinoma, where Lipiodol Ultra-Fluid was used as a procedure visualizer (contrast agent), a drug vehicle (drug carrier), and an embolic. The approved indications for Lipiodol Ultra-Fluid may vary according to countries. Please refer to local SmPC for further information.
Conventional transarterial chemo-embolization (cTACE) is a minimally invasive procedure which consists of mixing Lipiodol Ultra-Fluid with an anticancer drug and injecting this treatment trans-arterially in the liver as a loco-regional targeted chemotherapy, in which Lipiodol Ultra-Fluid acts as a contrast agent, a drug eluting vehicle and a dual arterio-portal transient embolic . cTACE was first performed in Japan in 1982 and then used effectively throughout Asia, Europe, the Middle East and Africa, as well as North America.
Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com.
Globe Newswire: 17:23 GMT Tuesday 3rd December 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.